Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report

BACKGROUND: Approximately 2–7% of patients with non-small cell lung cancer harbor anaplastic lymphoma kinase (ALK) rearrangement events. Of note, typical ALK actionable rearrangements are sensitive to treatment with tyrosine kinase inhibitors (TKIs). However, different types of ALK fusion influence...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xingyu, He, Yuqi, Wang, Yin, Lei, Yan, Su, Xiaoxing, Liu, Yifan, Wu, Shuangxiu, He, Zhengfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486277/
https://www.ncbi.nlm.nih.gov/pubmed/34611409
http://dx.doi.org/10.2147/OTT.S319845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486277/
https://www.ncbi.nlm.nih.gov/pubmed/34611409
http://dx.doi.org/10.2147/OTT.S319845

Ejemplares similares